- Home
- CXII vs ASMB Comparison
CXII vs ASMB Comparison
Compare CXII & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CXII | ASMB |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 597.4M | 512.1M |
| IPO Year | 2026 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CXII | ASMB |
|---|---|---|
| Price | $10.74 | $248.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $44.20 |
| AVG Volume (30 Days) | 61.2K | ★ 221.7K |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $638.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.05 | $20.23 |
| 52 Week High | $10.90 | $39.71 |
Technical Indicators
Market Signals| Indicator | CXII | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 56.75 | 73.33 |
| Support Level | $10.59 | $25.86 |
| Resistance Level | $10.89 | $39.17 |
| Average True Range (ATR) | 0.11 | 1.79 |
| MACD | -0.01 | 0.79 |
| Stochastic Oscillator | 50.00 | 97.91 |
Price Performance
Historical ComparisonAbout CXII Churchill Capital Corp XII Class A Ordinary Shares
Churchill Capital Corp XII is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.